2017
DOI: 10.1007/s00134-017-4792-2
|View full text |Cite
|
Sign up to set email alerts
|

Have biomarkers failed in acute kidney injury? No

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 16 publications
0
4
0
Order By: Relevance
“…The above-mentioned examples clearly show that the biomarker universum is still under construction. Additionally, the ongoing discussion shows large discrepancies among scientists and clinicians regarding their accuracy and predictive value [ 24 , 25 , 26 ]. Yet, their diagnostic value is restricted to the short period between pre-AKI and AKI time points.…”
Section: Markers Of Injurymentioning
confidence: 99%
“…The above-mentioned examples clearly show that the biomarker universum is still under construction. Additionally, the ongoing discussion shows large discrepancies among scientists and clinicians regarding their accuracy and predictive value [ 24 , 25 , 26 ]. Yet, their diagnostic value is restricted to the short period between pre-AKI and AKI time points.…”
Section: Markers Of Injurymentioning
confidence: 99%
“…The AKI biomarkers are also hampered by comparison against the current gold standard, creatinine. 72 Creatinine is an imperfect measure as described earlier. Because AKI is defined by a rise in creatinine; however, the performances of biomarkers are often inextricably linked to the performance of creatinine.…”
Section: Identification and Fda Approval Of Timp2*igfbp7 And Methodolmentioning
confidence: 99%
“…In AKI substages, the concept of subclinical AKI (sub-AKI) emerges to designate an episode of AKI unrecognized due to the absence of oliguria or rise in serum creatinine (SCr) level, and AKI substages A and B arise in attempting to subcategorize AKI stages by the absence or presence of biomarkers [ 3 , 7 , 8 , 10 12 ]. However, there remains a gap between these recommendations and the clinical application, and whether elevation in biomarkers without any changes in SCr/oliguria or a change in SCr/oliguria without any change of damage biomarker is associated with worse kidney and patient outcomes remains elusive [ 7 , 8 , 13 15 ]. This is particularly true in children, because the results obtained in adults seem difficult to be transferred directly into the pediatric field, where the results and their interpretation are age-dependent [ 16 , 17 ].…”
Section: Introductionmentioning
confidence: 99%